Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095778 | 0.79 | CRHR1 (0.36) | RORCCYP19A1CRHR1POLQMEN1 | |
| SCHEMBL4095773 | 0.79 | PDE2A (0.38) | RORCCYP19A1CRHR1MEN1KMT2A | |
| SCHEMBL4101822 | 0.79 | CACNA1H (0.35) | NR1H2NR1H3POLBMEN1KMT2A | |
| SCHEMBL4095982 | 0.76 | CYP3A4 (0.35) | NR1H2NR1H3RORCLMNA | |
| SCHEMBL4107196 | 0.74 | RXFP1 (0.38) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4102310 | 0.73 | CRHR1 (0.33) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4107183 | 0.73 | CRHR1 (0.35) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4101972 | 0.73 | CRHR1 (0.33) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4090226 | 0.72 | METAP2 (0.37) | NR1H2NR1H3CRHR1LMNAGAA | |
| SCHEMBL4095952 | 0.72 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | NR1H2 389/4885NR1H3 576/4885RORC 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.